These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer. Bhatta-Dhar N, Reuther AM, Zippe C, Klein EA. Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451 [Abstract] [Full Text] [Related]
5. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer. Lughezzani G, Gallina A, Larcher A, Briganti A, Capitanio U, Suardi N, Lista G, Abrate A, Sangalli MN, Buffi N, Cestari A, Guazzoni G, Rigatti P, Montorsi F. BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441 [Abstract] [Full Text] [Related]
6. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Da Pozzo LF, Cozzarini C, Briganti A, Suardi N, Salonia A, Bertini R, Gallina A, Bianchi M, Fantini GV, Bolognesi A, Fazio F, Montorsi F, Rigatti P. Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184 [Abstract] [Full Text] [Related]
7. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. Steuber T, Budäus L, Walz J, Zorn KC, Schlomm T, Chun F, Ahyai S, Fisch M, Sauter G, Huland H, Graefen M, Haese A. BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833 [Abstract] [Full Text] [Related]
10. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ, Blute ML. J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719 [Abstract] [Full Text] [Related]
13. Differing risk of cancer death among patients with lymph node metastasis after radical prostatectomy and pelvic lymph node dissection: identification of risk categories according to number of positive nodes and Gleason score. Schiavina R, Borghesi M, Brunocilla E, Manferrari F, Fiorentino M, Vagnoni V, Baccos A, Pultrone CV, Rocca GC, Rizzi S, Martorana G. BJU Int; 2013 Jun; 111(8):1237-44. PubMed ID: 23331345 [Abstract] [Full Text] [Related]
15. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy. Weckermann D, Goppelt M, Dorn R, Wawroschek F, Harzmann R. BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707 [Abstract] [Full Text] [Related]
16. Prognostic value of surgical margin status for biochemical recurrence following radical prostatectomy. Hashimoto K, Masumori N, Takei F, Fukuta F, Takahashi A, Itoh N, Hasegawa T, Tsukamoto T. Jpn J Clin Oncol; 2008 Jan; 38(1):31-5. PubMed ID: 18203710 [Abstract] [Full Text] [Related]
19. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Briganti A, Joniau S, Gontero P, Abdollah F, Passoni NM, Tombal B, Marchioro G, Kneitz B, Walz J, Frohneberg D, Bangma CH, Graefen M, Tizzani A, Frea B, Karnes RJ, Montorsi F, Van Poppel H, Spahn M. Eur Urol; 2012 Mar; 61(3):584-92. PubMed ID: 22153925 [Abstract] [Full Text] [Related]
20. Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer. Briganti A, Capitanio U, Chun FK, Gallina A, Suardi N, Salonia A, Da Pozzo LF, Colombo R, Di Girolamo V, Bertini R, Guazzoni G, Karakiewicz PI, Montorsi F, Rigatti P. Eur Urol; 2008 Oct; 54(4):794-802. PubMed ID: 18514383 [Abstract] [Full Text] [Related] Page: [Next] [New Search]